0000313616-20-000112.txt : 20200521 0000313616-20-000112.hdr.sgml : 20200521 20200521164915 ACCESSION NUMBER: 0000313616-20-000112 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20200331 ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200521 DATE AS OF CHANGE: 20200521 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DANAHER CORP /DE/ CENTRAL INDEX KEY: 0000313616 STANDARD INDUSTRIAL CLASSIFICATION: INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, AND CONTROL [3823] IRS NUMBER: 591995548 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-08089 FILM NUMBER: 20902520 BUSINESS ADDRESS: STREET 1: 2200 PENNSYLVANIA AVE. N.W. STREET 2: SUITE 800W CITY: WASHINGTON STATE: DC ZIP: 20037-1701 BUSINESS PHONE: 2028280850 MAIL ADDRESS: STREET 1: 2200 PENNSYLVANIA AVE. N.W. STREET 2: SUITE 800W CITY: WASHINGTON STATE: DC ZIP: 20037-1701 FORMER COMPANY: FORMER CONFORMED NAME: DMG INC DATE OF NAME CHANGE: 19850221 8-K/A 1 dhr-2020biopharma8xka.htm 8-K/A Document
false0000313616 0000313616 2020-03-31 2020-03-31 0000313616 dhr:FloatingRateSeniorNotesDue2022Member 2020-03-31 2020-03-31 0000313616 dhr:A1.2SeniorNotesDue2027Member 2020-03-31 2020-03-31 0000313616 us-gaap:CommonStockMember 2020-03-31 2020-03-31 0000313616 us-gaap:SeriesAPreferredStockMember 2020-03-31 2020-03-31 0000313616 dhr:A1.35SeniorNotesDue2039Member 2020-03-31 2020-03-31 0000313616 dhr:A1.7SeniorNotesDue2022Member 2020-03-31 2020-03-31 0000313616 dhr:A1.8SeniorNotesDue2049Member 2020-03-31 2020-03-31 0000313616 dhr:A0.75SeniorNotesDue2031Member 2020-03-31 2020-03-31 0000313616 dhr:A1.7SeniorNotesDue2024Member 2020-03-31 2020-03-31 0000313616 dhr:A2.1SeniorNotesDue2026Member 2020-03-31 2020-03-31 0000313616 dhr:A2.5SeniorNotesDue2030Member 2020-03-31 2020-03-31 0000313616 dhr:A0.2SeniorNotesDue2026Member 2020-03-31 2020-03-31 0000313616 dhr:A0.45SeniorNotesDue2028Member 2020-03-31 2020-03-31 0000313616 dhr:A2.5SeniorNotesDue2025Member 2020-03-31 2020-03-31 0000313616 us-gaap:SeriesBPreferredStockMember 2020-03-31 2020-03-31


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________________
FORM 8-K/A
(Amendment No. 1)
_____________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): March 31, 2020
_____________________________________________
dhrlogofor8ksa50.jpg
DANAHER CORPORATION
 
(Exact Name of Registrant as Specified in Its Charter)
 
__________________
Delaware
 
001-08089
 
59-1995548
(State or Other Jurisdiction of Incorporation)
 
(Commission File Number)
 
(IRS Employer Identification No.)
 
 
 
 
2200 Pennsylvania Avenue, NW
 
 
 
20037-1701
Suite 800W
 
 
 
Washington,
DC
 
 
 
(Address of Principal Executive Offices)
 
 
 
(Zip Code)
202-828-0850
(Registrant’s Telephone Number, Including Area Code)
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
_____________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common stock, $0.01 par value
DHR
New York Stock Exchange
4.75% Mandatory Convertible Preferred Stock, Series A, without par value
DHR.PRA
New York Stock Exchange
5.00% Mandatory Convertible Preferred Stock, Series B, without par value
DHR.PRB
New York Stock Exchange
Floating Rate Senior Notes due 2022
DHR F 06/30/22
New York Stock Exchange
1.700% Senior Notes due 2022
DHR 1.7 01/04/22
New York Stock Exchange
1.700% Senior Notes due 2024
DHR 1.7 03/30/24
New York Stock Exchange
2.500% Senior Notes due 2025
DHR 2.5 07/08/25
New York Stock Exchange
0.200% Senior Notes due 2026
DHR 0.2 03/18/26
New York Stock Exchange
2.100% Senior Notes due 2026
DHR 2.1 09/30/26
New York Stock Exchange
1.200% Senior Notes due 2027
DHR 1.2 06/30/27
New York Stock Exchange
0.450% Senior Notes due 2028
DHR 0.45 03/18/28
New York Stock Exchange
2.500% Senior Notes due 2030
DHR 2.5 03/30/30
New York Stock Exchange
0.750% Senior Notes due 2031
DHR 0.75 09/18/31
New York Stock Exchange
1.350% Senior Notes due 2039
DHR 1.35 09/18/39
New York Stock Exchange
1.800% Senior Notes due 2049
DHR 1.8 09/18/49
New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
 
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐





Item 2.01    Completion of Acquisition or Disposition of Assets.
On April 1, 2020, Danaher Corporation (the “Company”) filed a Current Report on Form 8-K reporting that, on March 31, 2020, the Company completed the acquisition of certain equity interests and assets, and assumption of certain liabilities, of the Biopharma business of the Life Sciences business of the General Electric Company (the “Biopharma Business”). This Amendment No. 1 amends the Current Report on Form 8-K filed on April 1, 2020 to provide the pro forma financial information required by Item 9.01 of Form 8-K, which was omitted from the initial filing in reliance on Items 9.01(a)(4) and 9.01(b)(2) of Form 8-K.
Item 9.01    Financial Statements and Exhibits.
(a)    Pro Forma Financial Information.
The unaudited pro forma condensed combined financial statements of the Company with respect to the transaction described in Item 2.01 are filed as Exhibit 99.1 to this amendment and incorporated herein by reference. 
(b)    Exhibits:
Exhibit Number
 
Exhibit Description
99.1
 
104
 
Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)





SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
DANAHER CORPORATION
 
 
By:
/s/ Robert S. Lutz
Name:
Robert S. Lutz
Title:
Senior Vice President and Chief Accounting Officer
Date: May 21, 2020



 EX-99.1 2 ex-991unauditedproform.htm UNAUDITED PROFORMA FINANCIAL INFORMATION Exhibit
Exhibit 99.1

UNAUDITED PRO FORMA FINANCIAL INFORMATION
DANAHER CORPORATION AND GE BIOPHARMA
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENT OF EARNINGS
DESCRIPTION OF TRANSACTION
On March 31, 2020, pursuant to the equity and asset purchase agreement, dated as of February 25, 2019 and as subsequently amended and restated as of March 31, 2020 (the “Purchase Agreement”), by and between Danaher Corporation (“Danaher” or the “Company”) and General Electric Company (“GE”), Danaher completed the acquisition of the Biopharma business of the Life Sciences business of GE (“GE Biopharma” or the “Biopharma business”) through the acquisition of certain assets and the assumption of certain liabilities, as well as the acquisition of the equity of certain subsidiaries of GE, for a cash purchase price of approximately $20.7 billion, subject to certain adjustments, and the assumption of approximately $0.4 billion of pension liabilities (the “Acquisition” or the “Cytiva Acquisition”). The Biopharma business, now known as Cytiva, is a leading provider of instruments, consumables and software that support the research, discovery, process development and manufacturing workflows of biopharmaceutical drugs. In connection with the Cytiva Acquisition, the Company also entered into a transition services agreement with General Electric Company for certain administrative and operational services, and a distribution agreement in certain countries until such operations are transferred to the Company.
The Company financed the $20.7 billion purchase price with approximately:
•
$3.0 billion of net proceeds from the March 1, 2019 underwritten public offerings of its Common Stock and Mandatory Convertible Preferred Stock (“MCPS”);
•
$10.8 billion of net proceeds from the issuance of euro-denominated and U.S. dollar-denominated long-term debt in the second half of 2019;
•
$2.5 billion in borrowings from the Company’s 5-year revolving credit facility; and
•
$4.4 billion from the aggregate of cash on hand and proceeds from commercial paper borrowings.
As a condition to obtaining certain regulatory approvals for the closing of the transaction, the Company was required to divest certain of its existing product lines that in the aggregate generated revenues of approximately $170 million in 2019. On April 30, 2020, the Company completed the sale of the majority of these product lines for a cash purchase price of approximately $825 million and will recognize a gain on the sale in the second quarter of 2020. The divestiture of these product lines did not represent a strategic shift with a major effect on the Company's operations and financial results and will not be reported as a discontinued operation.
The unaudited pro forma condensed combined statement of earnings is based on the historical consolidated financial statements of Danaher and the historical combined financial statements of GE Biopharma presented on a carve-out basis after giving effect to the acquisition of Cytiva, the divestiture of certain product lines (as discussed above) and the financing discussed above, and after applying the assumptions, reclassifications and adjustments described in the accompanying notes to the unaudited pro forma condensed combined statement of earnings. The unaudited pro forma condensed combined statement of earnings is presented as if the Cytiva Acquisition and the financing had occurred on January 1, 2019. A pro forma statement of financial position reflecting the acquisition of Cytiva is not required since the acquisition is included in the Company’s consolidated balance sheet included in its Quarterly Report on Form 10-Q for the quarter ended April 3, 2020 filed with the Securities and Exchange Commission (“SEC”) on May 6, 2020.
The unaudited pro forma condensed combined statement of earnings reflecting the combination of Danaher and Cytiva is provided for informational purposes only. The unaudited pro forma condensed combined statement of earnings is not intended to be a complete presentation of Danaher’s results of operations had the Cytiva Acquisition occurred as of January 1, 2019. The unaudited pro forma condensed combined statement of earnings is not necessarily indicative of Danaher’s historical or future results of operations or financial condition had the Cytiva Acquisition been completed on the date indicated. In addition, the unaudited pro forma condensed combined statement of earnings does not purport to project the future financial position or operating results of the combined company.
The unaudited pro forma condensed combined statement of earnings of Danaher is based on information available at the time of presentation and assumptions that Danaher’s management believe are reasonable, that reflect the impact of events directly attributable to the Cytiva Acquisition that are factually supportable, and that are expected to have a continuing impact on Danaher.
The unaudited pro forma condensed combined statement of earnings was prepared using the acquisition method of accounting with Danaher treated as the acquirer. Accordingly, the historical consolidated financial information has been adjusted to give

1

effect to the impact of the consideration paid in connection with the Cytiva Acquisition. The total estimated purchase price has been allocated on a preliminary basis to assets acquired and liabilities assumed in connection with the Cytiva Acquisition based on their estimated fair values as of the completion of the acquisition. Definitive allocations will be performed and finalized based upon certain valuations and other studies that will be performed by Danaher with the assistance, in some cases, of outside valuation specialists. Accordingly, the purchase allocation pro forma adjustments are preliminary and have been made solely for the purpose of providing unaudited pro forma condensed combined financial information and are subject to revision based on a final determination of the purchase price allocation.
The unaudited pro forma condensed combined statement of earnings includes certain purchase accounting adjustments, including items expected to have a continuing impact on the combined results, such as increased amortization expense on acquired tangible and intangible assets. The unaudited pro forma condensed combined statement of earnings does not include the impacts of any revenue, cost or other operating synergies that may result from the merger.
The unaudited pro forma condensed combined statement of earnings does not reflect nonrecurring charges and gains resulting from the Cytiva Acquisition which do not have a continuing impact. The nonrecurring charges include transaction costs and integration preparation costs incurred by the Company. In addition, the Company will incur certain nonrecurring charges following the acquisition, primarily associated with recording fair value adjustments to acquired inventory and deferred revenue, that have not been included in the unaudited pro forma condensed combined statement of earnings as they do not have a continuing impact. The nonrecurring gains include the gain on the product line divestiture. The unaudited pro forma condensed combined statement of earnings does not reflect the costs associated with the transition services and distribution agreements with General Electric Company.
The unaudited pro forma condensed combined statement of earnings should be read in conjunction with:
(i)
Danaher’s audited consolidated financial statements, the accompanying notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in Danaher’s Annual Report on Form 10-K for the year ended December 31, 2019;
(ii)
Danaher’s unaudited consolidated condensed financial statements, the accompanying notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in Danaher’s Quarterly Report on Form 10-Q for the quarter ended April 3, 2020; and
(iii)
GE Biopharma’s audited annual combined financial statements as of and for the year ended December 31, 2019 included as Exhibit 99.1 to the Company’s Current Report on Form 8-K filed with the SEC on April 1, 2020.


2

DANAHER CORPORATION AND GE BIOPHARMA
UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF EARNINGS
($ and shares in millions, except per share amounts)

 
For the Year Ended December 31, 2019
 
Danaher (a)
 
Cytiva (b)
 
Pro Forma Adjustments
 
Pro Forma Combined
Sales
$
17,911.1

 
$
3,289.0

 
$
(195.7
)
(c)(d)
$
21,004.4

Cost of sales
(7,927.4
)
 
(1,246.0
)
 
150.6

(c)(d)(e)(f)
(9,022.8
)
Gross profit
9,983.7

 
2,043.0

 
(45.1
)
 
11,981.6

Operating costs:
 
 
 
 
 
 
 
Selling, general and administrative expenses
(5,588.3
)
 
(567.0
)
 
(531.3
)
(d)(f)(k)(n)
(6,686.6
)
Research and development expenses
(1,126.0
)
 
(169.0
)
 
6.1

(d)
(1,288.9
)
Operating profit
3,269.4

 
1,307.0

 
(570.3
)
 
4,006.1

Nonoperating income (expense):
 
 
 
 
 
 
 
Other income, net
12.0

 
75.0

 
(5.3
)
(l)(m)
81.7

Loss on early extinguishment of borrowings
(6.5
)
 
—

 
—

 
(6.5
)
Interest expense
(108.6
)
 
(30.0
)
 
(159.4
)
(h)(i)(l)
(298.0
)
Interest income
139.0

 
—

 
(128.8
)
(g)
10.2

Earnings from continuing operations before income taxes
3,305.3

 
1,352.0

 
(863.8
)
 
3,793.5

Income taxes
(873.0
)
 
(378.0
)
 
283.3

(j)
(967.7
)
Net earnings from continuing operations
$
2,432.3

 
$
974.0

 
$
(580.5
)
 
$
2,825.8

Net earnings per common share from continuing operations (1):
 
 
 
 
 
 
 
Basic
$
3.31

 
 
 
 
 
$
3.83

Diluted
$
3.26

 
 
 
 
 
$
3.78

Average common stock and common equivalent shares outstanding:
 
 
 
 
 
 
Basic
715.0

 
 
 
2.0

(o)
717.0

Diluted
725.5

 
 
 
2.0

(o)
727.5

_________________
(1)
Net earnings per common share from continuing operations is calculated as net earnings from continuing operations less the mandatory convertible preferred stock dividends of $68.4 million for historical Danaher and $78.4 million for the pro forma combined Danaher. For diluted net earnings per common share from continuing operations, the interest on the Company’s convertible liquid yield option notes (“LYONs”) of $1.6 million for the year ended December 31, 2019 is added back to net earnings from continuing operations for both historical Danaher and for the pro forma combined Danaher.


See the accompanying Notes to the unaudited pro forma condensed combined statement of earnings.


3

DANAHER CORPORATION AND GE BIOPHARMA
NOTES TO THE UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF EARNINGS

NOTE 1. BASIS OF PRO FORMA PRESENTATION
On March 31, 2020, pursuant to the equity and asset purchase agreement, dated as of February 25, 2019 and as subsequently amended and restated as of March 31, 2020 (the “Purchase Agreement”), by and between Danaher Corporation (“Danaher” or the “Company”) and General Electric Company (“GE”), Danaher completed the acquisition of the Biopharma business of the Life Sciences business of GE (“GE Biopharma” or the “Biopharma business”) through the acquisition of certain assets and the assumption of certain liabilities, as well as the acquisition of the equity of certain subsidiaries of GE, for a cash purchase price of approximately $20.7 billion, subject to certain adjustments, and the assumption of approximately $0.4 billion of pension liabilities (the “Acquisition” or the “Cytiva Acquisition”). The Biopharma business, now known as Cytiva, is a leading provider of instruments, consumables and software that support the research, discovery, process development and manufacturing workflows of biopharmaceutical drugs. In connection with the Cytiva Acquisition, the Company also entered into a transition services agreement with General Electric Company for certain administrative and operational services, and a distribution agreement in certain countries until such operations are transferred to the Company.
The Company financed the $20.7 billion purchase price with approximately:
•
$3.0 billion of net proceeds from the March 1, 2019 underwritten public offerings of its Common Stock and Mandatory Convertible Preferred Stock (“MCPS”);
•
$10.8 billion of net proceeds from the issuance of euro-denominated and U.S. dollar-denominated long-term debt in the second half of 2019;
•
$2.5 billion in borrowings from the Company’s 5-year revolving credit facility; and
•
$4.4 billion from the aggregate of cash on hand and proceeds from commercial paper borrowings.
As a condition to obtaining certain regulatory approvals for the closing of the transaction, the Company was required to divest certain of its existing product lines that in the aggregate generated revenues of approximately $170 million in 2019. On April 30, 2020, the Company completed the sale of the majority of these product lines for a cash purchase price of approximately $825 million and will recognize a gain on the sale in the second quarter of 2020. The divestiture of these product lines did not represent a strategic shift with a major effect on the Company's operations and financial results and will not be reported as a discontinued operation.
The unaudited pro forma condensed combined statement of earnings is based on the historical consolidated financial statements of Danaher and the historical combined financial statements of GE Biopharma presented on a carve-out basis after giving effect to the acquisition of Cytiva, the divestiture of certain product lines (as discussed above) and the financing discussed above, and after applying the assumptions, reclassifications and adjustments described in the accompanying notes to the unaudited pro forma condensed combined statement of earnings. The unaudited pro forma condensed combined statement of earnings is presented as if the Cytiva Acquisition and the financing had occurred on January 1, 2019. A pro forma statement of financial position reflecting the acquisition of Cytiva is not required since the acquisition is included in the Company’s consolidated balance sheet included in its Quarterly Report on Form 10-Q for the quarter ended April 3, 2020 filed with the Securities and Exchange Commission (“SEC”) on May 6, 2020.
The unaudited pro forma condensed combined statement of earnings reflecting the combination of Danaher and Cytiva is provided for informational purposes only. The unaudited pro forma condensed combined statement of earnings is not intended to be a complete presentation of Danaher’s results of operations had the Cytiva Acquisition occurred as of January 1, 2019. The unaudited pro forma condensed combined statement of earnings is not necessarily indicative of Danaher’s historical or future results of operations or financial condition had the Cytiva Acquisition been completed on the date indicated. In addition, the unaudited pro forma condensed combined statement of earnings does not purport to project the future financial position or operating results of the combined company.
The unaudited pro forma condensed combined statement of earnings of Danaher is based on information available at the time of presentation and assumptions that Danaher’s management believe are reasonable, that reflect the impact of events directly attributable to the Cytiva Acquisition that are factually supportable, and that are expected to have a continuing impact on Danaher.
The unaudited pro forma condensed combined statement of earnings was prepared using the acquisition method of accounting with Danaher treated as the acquirer. Accordingly, the historical consolidated financial information has been adjusted to give

4

effect to the impact of the consideration paid in connection with the Cytiva Acquisition. The total estimated purchase price has been allocated on a preliminary basis to assets acquired and liabilities assumed in connection with the Cytiva Acquisition based on their estimated fair values as of the completion of the acquisition. Definitive allocations will be performed and finalized based upon certain valuations and other studies that will be performed by Danaher with the assistance, in some cases, of outside valuation specialists. Accordingly, the purchase allocation pro forma adjustments are preliminary and have been made solely for the purpose of providing unaudited pro forma condensed combined financial information and are subject to revision based on a final determination of the purchase price allocation.
The unaudited pro forma condensed combined statement of earnings includes certain purchase accounting adjustments, including items expected to have a continuing impact on the combined results, such as increased amortization expense on acquired tangible and intangible assets. The unaudited pro forma condensed combined statement of earnings does not include the impacts of any revenue, cost or other operating synergies that may result from the merger.
The unaudited pro forma condensed combined statement of earnings does not reflect nonrecurring charges and gains resulting from the Cytiva Acquisition which do not have a continuing impact. The nonrecurring charges include transaction costs and integration preparation costs incurred by the Company. In addition, the Company will incur certain nonrecurring charges following the acquisition, primarily associated with recording fair value adjustments to acquired inventory and deferred revenue, that have not been included in the unaudited pro forma condensed combined statement of earnings as they do not have a continuing impact. The nonrecurring gains include the gain on the product line divestiture. The unaudited pro forma condensed combined statement of earnings does not reflect the costs associated with the transition services and distribution agreements with General Electric Company.
In 2019, the Biopharma business sold an equity method investment and recorded a pre-tax gain on the sale of $35 million. The Biopharma business also sold its Forensics Business in 2019 and recorded a pre-tax gain on the sale of $23 million. Both of these gains are reflected within Other (income) and expense—net in the Combined Statement of Income of the Biopharma business. As these transactions are historical transactions of the Biopharma business, the pro forma financial information is required to include the historical gains on these sales even if the sales were completed by GE Biopharma prior to the acquisition by Danaher and will not recur in future periods.
The following table summarizes the preliminary purchase price allocation for the assets acquired and liabilities assumed based on the Company’s current best estimates ($ in millions):
Trade accounts receivable
$
488.3

Inventories
817.0

Property, plant and equipment
788.9

Definite-lived intangible assets subject to amortization:
 
Customer relationships
1,118.0

Developed technology
7,327.5

Tradenames and trademarks
557.5

Total definite-lived intangible assets subject to amortization
9,003.0

Indefinite-lived intangible assets:
 
Goodwill
11,497.2

Total indefinite-lived intangible assets
11,497.2

Trade accounts payable
(250.8
)
Pension liabilities
(417.2
)
Deferred tax liabilities
(796.6
)
Other assets and liabilities, net
(395.3
)
Net cash consideration
$
20,734.5

Definite-lived intangible assets acquired have estimated useful lives ranging from 9 to 16 years. The amortization related to the amortizable intangible assets is reflected as a pro forma adjustment to the unaudited pro forma condensed combined statement of earnings.
The value assigned to Cytiva’s customer relationships was determined by discounting the estimated cash flows associated with the existing customers as of the acquisition date taking into consideration expected attrition of the existing customer base. The estimated cash flows were based on revenues for those existing customers net of operating expenses and net contributory asset

5

charges associated with servicing those customers. The estimated revenues were based on estimated growth rates and customer renewal rates. Operating expenses were estimated based on the supporting infrastructure expected to sustain the assumed revenue growth rates. Net contributory asset charges were based on the estimated fair value of those assets that contribute to the generation of the estimated cash flows. The 10.5% discount rate utilized to discount the net cash flows of customer relationships to its present value was based on the risks associated with the cash flows taking into consideration the Company's weighted average cost of capital.
The value assigned to Cytiva’s developed technology was determined by discounting the estimated future cash flows associated with the existing developed technology to its present value. Developed technology, which comprises products that have reached technological feasibility, includes offerings in Cytiva’s portfolio of products. The revenue estimates used to value the developed technology were based on estimates of relevant market sizes and growth factors, expected trends in technology and the nature and expected timing of new product introductions by Cytiva and its competitors. The 10.5% discount rate utilized to discount the net cash flows of developed technology to its present value was based on the risks associated with the cash flows taking into consideration the Company’s weighted average cost of capital.
NOTE 2. PRO FORMA ADJUSTMENTS
Pro forma adjustments in the unaudited pro forma condensed combined statement of earnings are as follows:
(a)
Represents Danaher’s historical Consolidated Statement of Earnings for the year ended December 31, 2019.
(b)
Represents the operations of Cytiva derived from the historical Combined Statement Income of the GE Biopharma business prepared on a carve-out basis of accounting for the year ended December 31, 2019.
Unaudited Pro Forma Condensed Combined Statement of Earnings
(c)
Adjustment reflecting transactions between Cytiva and historical Danaher businesses previously recorded as third-party sales now reflected as intercompany transactions and eliminated.
(d)
Adjustment reflecting the Company’s divestiture of certain historical product lines required to obtain regulatory approval for the closing of the acquisition of Cytiva. In the aggregate, these product lines generated revenues of approximately $170 million in the year ended December 31, 2019.
(e)
Adjustment reflecting a net increase in depreciation expense of $11 million for the year ended December 31, 2019, reflecting the net impact of the fair value adjustments to property, plant, and equipment and modifications of the remaining useful lives of those assets.
(f)
Adjustment to reflect the estimated additional intangible asset amortization expense of $586 million for the year ended December 31, 2019 resulting from the fair value adjustments to Cytiva’s intangible assets.
(g)
Adjustment to reflect the elimination of interest income of $129 million for the year ended December 31, 2019, earned on deposited cash balances resulting from the historical financing of the Acquisition. The pro forma financial statement assumes the cash required for the purchase price is generated through financing on January 1, 2019 and immediately used for the acquisition instead of deposited in financial institutions.
(h)
Adjustment to reflect an increase in interest expense of $188 million for the year ended December 31, 2019. Additional interest expense of $84 million relates to the approximately $10.8 billion of U.S. dollar-denominated and euro-denominated notes issued by Danaher. Additional interest expense of $47 million relates the $2.5 billion borrowing under the Company’s 5-year revolving credit facility. Since Danaher used $4.4 billion of proceeds from commercial paper borrowings and cash on hand that was generated by Danaher prior to the closing, the pro forma financial statement assumes that as of January 1, 2019, Danaher would have to borrow an additional approximately $3.6 billion to close the acquisition as of that date after considering the cash proceeds of approximately $0.8 billion from the product line divestiture. These borrowings consist initially of approximately $0.6 billion of U.S. dollar-denominated commercial paper and approximately $3.0 billion of euro-denominated commercial paper with $2.5 billion of the commercial paper borrowings subsequently replaced with proceeds from a $2.5 billion borrowing from the Company’s 364-day credit facility following the acquisition. Additional interest expense of $57 million relates to the $2.5 billion borrowing under the 364-day credit facility and the commercial paper. The effect of a 0.1% change in the assumed interest rates on the Company’s credit facilities and commercial paper borrowings for the acquisition would result in additional pro forma interest expense of approximately $6 million for the year ended December 31, 2019.
(i)
Adjustment to reflect the elimination of interest expense of $17 million for the year ended December 31, 2019, related

6

to interest expense incurred as part of the monetization of a portion of accounts receivables through historical GE factoring programs as well as other historical interest expense paid to other GE subsidiaries.
(j)
Adjustment to Cytiva’s historical effective tax rate to approximately 22%, which the Company expects to be the approximate income tax rate for Cytiva as part of the combined entity.  The effective tax rate of 22% was also applied to the pretax earnings/(loss) of the pro forma adjustments for the year ended December 31, 2019.
(k)
Adjustment to remove transaction costs and integration preparation costs of $93 million ($84 million after tax) incurred by Danaher during the year ended December 31, 2019.
(l)
Reclassification to Cytiva’s presentation of the non-service cost components of pension and other postretirement benefit expense of $12 million for the year ended December 31, 2019 from interest expense to other income (expense), in order to conform to the presentation used in the unaudited pro forma condensed combined statement of earnings.
(m)
Adjustment to reflect a reduction in pension related costs of $7 million for the year ended December 31, 2019 attributable to the impact of the fair value adjustments to Cytiva’s pension and other post-retirement benefit obligations.
(n)
Reclassification to the presentation of Cytiva’s $1 million from net losses attributable to noncontrolling interests to selling, general and administrative expenses for the year ended December 31, 2019, in order to conform to the presentation used in the unaudited pro forma condensed combined statement of earnings.
(o)
Adjustment reflecting the increase of $10 million in MCPS dividends and 2.0 million in average common stock and common equivalent shares outstanding for the calculation of both basic and diluted net earnings per common share from continuing operations, resulting from the assumption in the pro forma financial statement that the financing for the Acquisition occurs on January 1, 2019. The increase in the MCPS dividends is reflected in the calculation of basic and diluted net earnings per common share from continuing operations, as the MCPS dividends are deducted from net earnings from continuing operations in the calculation of basic and diluted earnings per share from continuing operations.

NOTE 3. NONRECURRING ITEMS
In connection with the Company’s acquisition of Cytiva, the Company has incurred and will incur certain nonrecurring charges and gains following the Acquisition that have not been included in the unaudited pro forma condensed combined statement of earnings for the year ended December 31, 2019. These nonrecurring charges include $320 million ($249 million after tax) and $51 million ($40 million after tax) of expense associated with recording fair values adjustments to acquired inventory and deferred revenue, respectively.
Nonrecurring charges resulting from the acquisition that are not included in the unaudited pro forma condensed combined statement of earnings and that will not have a continuing impact on the combined Danaher and Cytiva future results are comprised of transaction costs and integration preparation costs of $180 million ($161 million after tax).
As a condition to obtaining certain regulatory approvals for the closing of the transaction, the Company was required to divest certain of its existing product lines that in the aggregate generated revenues of approximately $170 million in 2019. On April 30, 2020, the Company completed the sale of the majority of these product lines for a cash purchase price of approximately $825 million. The nonrecurring gain from the product line divestiture is not reflected in the unaudited pro forma condensed combined statement of earnings.
These nonrecurring items are directly attributable to the Acquisition and will not have a continuing impact on the combined Danaher and Cytiva future results.

NOTE 4. FORWARD-LOOKING STATEMENTS
This unaudited pro forma condensed combined statement of earnings is forward-looking and involves a number of risks and uncertainties. There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include risks and uncertainties related to, among other things: the possibility that the expected synergies from the acquisition of Cytiva will not be realized, or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; the possibility that disruption from the Acquisition may make it more difficult to maintain business and operational relationships; difficulty in integrating personnel, operations and financial and other controls and systems, and retaining key employees and customers; Danaher’s and Cytiva’s ability to accurately predict

7

future market conditions; the risk of new and changing regulation and public policy in the U.S. and internationally; and the exposure to litigation and/or regulatory actions or sanctions resulting from activities of Cytiva prior to the acquisition. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in Danaher’s SEC filings, including Danaher’s Annual Report on Form 10-K for the year ended December 31, 2019 and Quarterly Report on Form 10-Q for the quarter ended April 3, 2020. These forward-looking statements speak only as of the date of this report and Danaher does not assume any obligation to update or revise any forward-looking statements, whether as a result of new information, future events and developments or otherwise, except as required by law.

8
 EX-101.SCH 3 dhr-20200331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001000 - Document - Cover Page Document link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 dhr-20200331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 dhr-20200331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 dhr-20200331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Entity Listings [Table] Entity Listings [Table] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock [Member] Common Stock [Member] Series A Preferred Stock [Member] Series A Preferred Stock [Member] Series B Preferred Stock [Member] Series B Preferred Stock [Member] Floating Rate Senior Notes Due 2022 [Member] Floating Rate Senior Notes Due 2022 [Member] Floating Rate Senior Notes Due 2022 Member [Member] 1.7% Senior Notes Due 2022 [Member] 1.7% Senior Notes Due 2022 [Member] 1.7% Senior Notes Due 2022 [Member] 1.7% Senior Notes Due 2024 [Member] 1.7% Senior Notes Due 2024 [Member] 1.7% Senior Notes Due 202 [Member] 2.5% Senior Notes Due 2025 [Member] 2.5% Senior Notes Due 2025 [Member] 2.5% Senior Notes Due 2025 [Member] 0.2% Senior Notes Due 2026 [Member] 0.2% Senior Notes Due 2026 [Member] 0.2% Senior Notes Due 2026 [Member] 2.1% Senior Notes Due 2026 [Member] 2.1% Senior Notes Due 2026 [Member] 2.1% Senior Notes Due 2026 [Member] 1.2% Senior Notes Due 2027 [Member] 1.2% Senior Notes Due 2027 [Member] 1.2% Senior Notes Due 2027 [Member] 0.45% Senior Notes Due 2028 [Member] 0.45% Senior Notes Due 2028 [Member] 0.45% Senior Notes Due 2028 [Member] 2.5% Senior Notes Due 2030 [Member] 2.5% Senior Notes Due 2030 [Member] 2.5% Senior Notes Due 2030 [Member] 0.75% Senior Notes Due 2031 [Member] 0.75% Senior Notes Due 2031 [Member] 0.75% Senior Notes Due 2031 [Member] 1.35% Senior Notes Due 2039 [Member] 1.35% Senior Notes Due 2039 [Member] 1.35% Senior Notes Due 2039 [Member] 1.8% Senior Notes Due 2049 [Member] 1.8% Senior Notes Due 2049 [Member] 1.8% Senior Notes Due 2049 [Member] Entity Listings [Line Items] Entity Listings [Line Items] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key EX-101.PRE 7 dhr-20200331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 dhrlogofor8ksa50.jpg begin 644 dhrlogofor8ksa50.jpg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end XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 dhr-2020biopharma8xka_htm.xml IDEA: XBRL DOCUMENT 0000313616 2020-03-31 2020-03-31 0000313616 dhr:FloatingRateSeniorNotesDue2022Member 2020-03-31 2020-03-31 0000313616 dhr:A1.2SeniorNotesDue2027Member 2020-03-31 2020-03-31 0000313616 us-gaap:CommonStockMember 2020-03-31 2020-03-31 0000313616 us-gaap:SeriesAPreferredStockMember 2020-03-31 2020-03-31 0000313616 dhr:A1.35SeniorNotesDue2039Member 2020-03-31 2020-03-31 0000313616 dhr:A1.7SeniorNotesDue2022Member 2020-03-31 2020-03-31 0000313616 dhr:A1.8SeniorNotesDue2049Member 2020-03-31 2020-03-31 0000313616 dhr:A0.75SeniorNotesDue2031Member 2020-03-31 2020-03-31 0000313616 dhr:A1.7SeniorNotesDue2024Member 2020-03-31 2020-03-31 0000313616 dhr:A2.1SeniorNotesDue2026Member 2020-03-31 2020-03-31 0000313616 dhr:A2.5SeniorNotesDue2030Member 2020-03-31 2020-03-31 0000313616 dhr:A0.2SeniorNotesDue2026Member 2020-03-31 2020-03-31 0000313616 dhr:A0.45SeniorNotesDue2028Member 2020-03-31 2020-03-31 0000313616 dhr:A2.5SeniorNotesDue2025Member 2020-03-31 2020-03-31 0000313616 us-gaap:SeriesBPreferredStockMember 2020-03-31 2020-03-31 false 0000313616 8-K/A 2020-03-31 DANAHER CORPORATION DE 001-08089 59-1995548 2200 Pennsylvania Avenue, NW 20037-1701 Suite 800W Washington, DC 202 828-0850 false false false false Common stock, $0.01 par value DHR NYSE 4.75% Mandatory Convertible Preferred Stock, Series A, without par value DHR.PRA NYSE 5.00% Mandatory Convertible Preferred Stock, Series B, without par value DHR.PRB NYSE Floating Rate Senior Notes due 2022 DHR F 06/30/22 NYSE 1.700% Senior Notes due 2022 DHR 1.7 01/04/22 NYSE 1.700% Senior Notes due 2024 DHR 1.7 03/30/24 NYSE 2.500% Senior Notes due 2025 DHR 2.5 07/08/25 NYSE 0.200% Senior Notes due 2026 DHR 0.2 03/18/26 NYSE 2.100% Senior Notes due 2026 DHR 2.1 09/30/26 NYSE 1.200% Senior Notes due 2027 DHR 1.2 06/30/27 NYSE 0.450% Senior Notes due 2028 DHR 0.45 03/18/28 NYSE 2.500% Senior Notes due 2030 DHR 2.5 03/30/30 NYSE 0.750% Senior Notes due 2031 DHR 0.75 09/18/31 NYSE 1.350% Senior Notes due 2039 DHR 1.35 09/18/39 NYSE 1.800% Senior Notes due 2049 DHR 1.8 09/18/49 NYSE false EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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htm IDEA: XBRL DOCUMENT v3.20.1
Cover Page Document
Mar. 31, 2020
Entity Listings [Line Items]  
Document Type 8-K/A
Document Period End Date Mar. 31, 2020
Entity Registrant Name DANAHER CORPORATION
Entity Incorporation, State or Country Code DE
Entity File Number 001-08089
Entity Tax Identification Number 59-1995548
Entity Address, Address Line One 2200 Pennsylvania Avenue, NW
Entity Address, Address Line Two Suite 800W
Entity Address, City or Town Washington,
Entity Address, State or Province DC
Entity Address, Postal Zip Code 20037-1701
City Area Code 202
Local Phone Number 828-0850
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0000313616
Common Stock [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Common stock, $0.01 par value
Trading Symbol DHR
Security Exchange Name NYSE
Series A Preferred Stock [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 4.75% Mandatory Convertible Preferred Stock, Series A, without par value
Trading Symbol DHR.PRA
Security Exchange Name NYSE
Series B Preferred Stock [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 5.00% Mandatory Convertible Preferred Stock, Series B, without par value
Trading Symbol DHR.PRB
Security Exchange Name NYSE
Floating Rate Senior Notes Due 2022 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Floating Rate Senior Notes due 2022
Trading Symbol DHR F 06/30/22
Security Exchange Name NYSE
1.7% Senior Notes Due 2022 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 1.700% Senior Notes due 2022
Trading Symbol DHR 1.7 01/04/22
Security Exchange Name NYSE
1.7% Senior Notes Due 2024 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 1.700% Senior Notes due 2024
Trading Symbol DHR 1.7 03/30/24
Security Exchange Name NYSE
2.5% Senior Notes Due 2025 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 2.500% Senior Notes due 2025
Trading Symbol DHR 2.5 07/08/25
Security Exchange Name NYSE
0.2% Senior Notes Due 2026 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 0.200% Senior Notes due 2026
Trading Symbol DHR 0.2 03/18/26
Security Exchange Name NYSE
2.1% Senior Notes Due 2026 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 2.100% Senior Notes due 2026
Trading Symbol DHR 2.1 09/30/26
Security Exchange Name NYSE
1.2% Senior Notes Due 2027 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 1.200% Senior Notes due 2027
Trading Symbol DHR 1.2 06/30/27
Security Exchange Name NYSE
0.45% Senior Notes Due 2028 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 0.450% Senior Notes due 2028
Trading Symbol DHR 0.45 03/18/28
Security Exchange Name NYSE
2.5% Senior Notes Due 2030 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 2.500% Senior Notes due 2030
Trading Symbol DHR 2.5 03/30/30
Security Exchange Name NYSE
0.75% Senior Notes Due 2031 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 0.750% Senior Notes due 2031
Trading Symbol DHR 0.75 09/18/31
Security Exchange Name NYSE
1.35% Senior Notes Due 2039 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 1.350% Senior Notes due 2039
Trading Symbol DHR 1.35 09/18/39
Security Exchange Name NYSE
1.8% Senior Notes Due 2049 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 1.800% Senior Notes due 2049
Trading Symbol DHR 1.8 09/18/49
Security Exchange Name NYSE
XML 14 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "dhr-2020biopharma8xka.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 16, "dts": { "calculationLink": { "local": [ "dhr-20200331_cal.xml" ] }, "definitionLink": { "local": [ "dhr-20200331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "dhr-2020biopharma8xka.htm" ] }, "labelLink": { "local": [ "dhr-20200331_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "dhr-20200331_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "dhr-20200331.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 43, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 12, "memberStandard": 3, "nsprefix": "dhr", "nsuri": "http://www.danaher.com/20200331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "dhr-2020biopharma8xka.htm", "contextRef": "D2020Q1filedatebio", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page Document", "role": "http://www.danaher.com/role/CoverPageDocument", "shortName": "Cover Page Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "dhr-2020biopharma8xka.htm", "contextRef": "D2020Q1filedatebio", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 15, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityListingsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Listings [Line Items]", "terseLabel": "Entity Listings [Line Items]" } } }, "localname": "EntityListingsLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "stringItemType" }, "dei_EntityListingsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container for exchange listing information for an entity", "label": "Entity Listings [Table]", "terseLabel": "Entity Listings [Table]" } } }, "localname": "EntityListingsTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dhr_A0.2SeniorNotesDue2026Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "0.2% Senior Notes Due 2026 [Member]", "label": "0.2% Senior Notes Due 2026 [Member]", "terseLabel": "0.2% Senior Notes Due 2026 [Member]" } } }, "localname": "A0.2SeniorNotesDue2026Member", "nsuri": "http://www.danaher.com/20200331", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "domainItemType" }, "dhr_A0.45SeniorNotesDue2028Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "0.45% Senior Notes Due 2028 [Member]", "label": "0.45% Senior Notes Due 2028 [Member]", "terseLabel": "0.45% Senior Notes Due 2028 [Member]" } } }, "localname": "A0.45SeniorNotesDue2028Member", "nsuri": "http://www.danaher.com/20200331", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "domainItemType" }, "dhr_A0.75SeniorNotesDue2031Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "0.75% Senior Notes Due 2031 [Member]", "label": "0.75% Senior Notes Due 2031 [Member]", "terseLabel": "0.75% Senior Notes Due 2031 [Member]" } } }, "localname": "A0.75SeniorNotesDue2031Member", "nsuri": "http://www.danaher.com/20200331", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "domainItemType" }, "dhr_A1.2SeniorNotesDue2027Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "1.2% Senior Notes Due 2027 [Member]", "label": "1.2% Senior Notes Due 2027 [Member]", "terseLabel": "1.2% Senior Notes Due 2027 [Member]" } } }, "localname": "A1.2SeniorNotesDue2027Member", "nsuri": "http://www.danaher.com/20200331", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "domainItemType" }, "dhr_A1.35SeniorNotesDue2039Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "1.35% Senior Notes Due 2039 [Member]", "label": "1.35% Senior Notes Due 2039 [Member]", "terseLabel": "1.35% Senior Notes Due 2039 [Member]" } } }, "localname": "A1.35SeniorNotesDue2039Member", "nsuri": "http://www.danaher.com/20200331", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "domainItemType" }, "dhr_A1.7SeniorNotesDue2022Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "1.7% Senior Notes Due 2022 [Member]", "label": "1.7% Senior Notes Due 2022 [Member]", "terseLabel": "1.7% Senior Notes Due 2022 [Member]" } } }, "localname": "A1.7SeniorNotesDue2022Member", "nsuri": "http://www.danaher.com/20200331", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "domainItemType" }, "dhr_A1.7SeniorNotesDue2024Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "1.7% Senior Notes Due 202 [Member]", "label": "1.7% Senior Notes Due 2024 [Member]", "terseLabel": "1.7% Senior Notes Due 2024 [Member]" } } }, "localname": "A1.7SeniorNotesDue2024Member", "nsuri": "http://www.danaher.com/20200331", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "domainItemType" }, "dhr_A1.8SeniorNotesDue2049Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "1.8% Senior Notes Due 2049 [Member]", "label": "1.8% Senior Notes Due 2049 [Member]", "terseLabel": "1.8% Senior Notes Due 2049 [Member]" } } }, "localname": "A1.8SeniorNotesDue2049Member", "nsuri": "http://www.danaher.com/20200331", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "domainItemType" }, "dhr_A2.1SeniorNotesDue2026Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2.1% Senior Notes Due 2026 [Member]", "label": "2.1% Senior Notes Due 2026 [Member]", "terseLabel": "2.1% Senior Notes Due 2026 [Member]" } } }, "localname": "A2.1SeniorNotesDue2026Member", "nsuri": "http://www.danaher.com/20200331", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "domainItemType" }, "dhr_A2.5SeniorNotesDue2025Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2.5% Senior Notes Due 2025 [Member]", "label": "2.5% Senior Notes Due 2025 [Member]", "terseLabel": "2.5% Senior Notes Due 2025 [Member]" } } }, "localname": "A2.5SeniorNotesDue2025Member", "nsuri": "http://www.danaher.com/20200331", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "domainItemType" }, "dhr_A2.5SeniorNotesDue2030Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2.5% Senior Notes Due 2030 [Member]", "label": "2.5% Senior Notes Due 2030 [Member]", "terseLabel": "2.5% Senior Notes Due 2030 [Member]" } } }, "localname": "A2.5SeniorNotesDue2030Member", "nsuri": "http://www.danaher.com/20200331", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "domainItemType" }, "dhr_FloatingRateSeniorNotesDue2022Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Floating Rate Senior Notes Due 2022 Member [Member]", "label": "Floating Rate Senior Notes Due 2022 [Member]", "terseLabel": "Floating Rate Senior Notes Due 2022 [Member]" } } }, "localname": "FloatingRateSeniorNotesDue2022Member", "nsuri": "http://www.danaher.com/20200331", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Series B Preferred Stock [Member]", "terseLabel": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.danaher.com/role/CoverPageDocument" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0000313616-20-000112-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000313616-20-000112-xbrl.zip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

S$8*RRQ(+6-K M'Y,2ZG? O!KBI2BP($C-\S =I: D$$;T9G$A\7*WBL@%7MIJJPKC%AU6*##, M0D^EB35-Z;G(.KCR7&0=9=/_4=AH3I&U QTHY[-9HNZ?(,O:^M<\K6X5K0F: M3/=O5!.(==#^29HQ'ONMNZ?JETPN $,'"GSG)-D8ABHDXA1)!554)@W$N%UH M-1IR^08?;R Q< OW;R!#I;%J&&/I*/AKU+'A0"998)357H72I5!$+D-9W,)4 M@,BD@-CTO]468;.0#'\6OE>>)]?MWADOH7 MU$Z%S&+.%,P%@M3?J9LOY]-Q M/E%4O5.HQ0,B[0X0D5F2:CQ)8X5F+8@*"&.74S6$ ;%MO..\J.XQXF4Q>0^4 MK%5)+ [:E''NT-E7K4FREDP&D\4H+T@RGVHF=J'FLFJ+*-?I1XV M"L@="T78N:0H)D6:CEI.BCPE55.&:2'!^75-3I>!6YF/1@I\XR1%T-:.<J[1%@T#MJCA+V%U3EE?EN-V4\1(*B%3+=4V4":@" MM*68G>79/2PFA(AWK":(>CE0(&5-D[H/93Y30%=-DZ9/1HQK/U-._2*N7!5< M]5$9^RHCWH4!5UIV159(X?>O2"W.^<[LN3PID+%JUWQ D2VMWJ'4LNF?9*JH M0Y!D$:""Q95L'I8N4ZL_)(2M6%CVN9//GLJ*)J3Y($.Z-B-0O&75(5=D:5XEM,G3_% MWZ_^I1[7U;^4^1I)4+7.ULB"*F%FVAUE.:]4#I+<,1JS1!5Q<9*,2WFB%0LV5#P9FJY0QM;T MB3QU,K-1!'^WE6\2%<0$1TI"7UKY^.*G93]>LM M:GU1L4JK"?NXW!OWH5__AE?W%^_^,,B'MQ\_#-,KK:QN)\"B$;RL-XJGZ>3V MY"*=LE+[PJZULWP:9^\%K4S_S4XPFE7OH9/-FC#>V22^Y6$<._KX(;TYX8VP MHOXS'0Y9)OX$^IVJ9L>U@V,?.*2R$.]ZS]Z]RIX MI-4V[*C>%+"6,3_/O0W^O[XH809L.'6Y^ :3SYE0W;S#W;; M&)*'#1M%V#.@7XZ#J8^(*WH:^)1$R%H-:5?!HX\(_M&Q;F%KJ_?]3::L M;R MXP>>?A,9@VD,P]%$VOED+,*3X;CH+3>Q'-^47/X%E8?F/QV5Z70VX;SO;[ZB M;JW9A/A9YO-"_!+9C)/%#(J)D,R@$.BZ)!,SR!\LGP!111LSF+A\V&RUK, P!]"_C[R[/:2#DB^KKVF-"B##BN)+ M2J,#J_:6#Q83=+_Y^GUAQ'\_K^ !UQQ_$I?EZ>B\RI,_W)NT_!V8^7LTR<%O MRR[/H- YR]*\^))7K SF#-Y(/K/I@!4'F_K5O+)+WF'QJ'XVA)9O9I,T2:NZ M3]H0L"FKMR8O1GJB'.G11QCJR7V&^J$O;:WN7'^K=S^6K+CXF&Q-G/VJ9*1M MB)UL*&1C6<+/I],\$\]?C5 LBVR-K9.&'=)P#@VQTOTJS'[!AJ]3+EI&V4E( MNRW1S;M(JSNO1CX6QD0]QDXZVJ7#?N7>:-L0.]EHEPUZ=^*,5P<FVPHA]C)1KO'L9TP?&6XT3+$3C;:9*-B8R\.WYW9&S-^TM4))NBOVUMW/I2S.)-M M^DFS,0R@DM08%'UHC]=;-MMHO";N[ >?B%X\22^SDX3Q4ZV:[5@/[AFO(7Y> MUVT,\LD07O'KET\78:"=7[@7X?FRRP\>L+8YV.)3>*ZY7P(M M_*?_L_OE[Z'FGW[^_.G\_-/IEVZ<%Q_ZQ1I!I M./?OY2P>\I/J>H.\JO+IB3&[:>TX?6B_ZPJ_/^2?ER9.T>G99ZTI,7?WM'$< M&A*L.]2@C#JKC6>4FJ89.1Z!Y[9KVD0/?:R3$#DF,O4(-W>[+3V&U+[DQQI^^VBUH*]' M+1YGUB2S"QA[%GZYT,["KZ=G%\^.J$\VKJ^_GIW_ZL+ +DXUL"078"XTK&NG M9QHVWP2/ER&L[Q"BIQO"::1=_!QJ#3NXLH&N?Z$!&3NZ\=PL>Y322$;+'4LM M'VD%F^5%I;U9_F8Q>)6LK#1VQ2&@)K/AVQ/MX2-7-/UA^SW7X[1B/7B2,(#9 MZR*>';7:"XS7.Y7AB6GH*'!T1"/3L:E/$=9UT\34X8M7,H/Q5;C18>U?[[0< M&[NW^<,IE!\/X]M;F"V6'7W\'!?)6-/Q.W'RJ\I8;/[OFZ?Q 0+URH"9R\;T M4BN+1&P:G^27.7"(_E'&)CK^G]GED19/*A5ITB8. XENJ7K MV+03>%:RD^4?S3GB+Q;]AXBT&H+.\?Y"0*_S*:^&_#_% MBKK$A9HSYE_?+PO=I9E832/&FM9\>:/I984K5E1I$D\6?:T5Y?T&RPA,?Y,? MS=\+Q6H^JJ>-U#QKB,%]I.8!QJ4=8]L@U%A_OX*193@Z^-R.[A+'UT.*H)AN M(=_UG< AVU^8G+'+M.1?9U9?@++;]P[<+^[/X1E$DV?@^+@7(IQLA\DZ": 0 MC,/Q*X>F1I/\>O%!RU,D._[V%VRA]Y*!/L?X#N-\+C-]*A#W*$CD/[:$CY^"W MF/"[3KUU3Z?^-5I/ZAP[AHVHL_SOMUE/:[?U--06$MLMM!;#:CVJFHYWV&/R MTNSQD^'?/>PQI2M[##;7(!8Q7:I'#@Y#V[0M;H]]8EHXHLZV/?Z4)7D!H9HX M)T$LC?CUD1%^/GQ8@,-/DN +%16;%?D5;X='. &;Q-<0[-S?:+]VH%:.#_K_ MJ@458NIU[.T1Z@;4LSWL!M@,J4VP$%33P$YH!]N"&H'8P6OY0N-.IQ$AW$,4 M0+*3ND[J\%KJL.N;1 ]-'_ZP$-$1LB,A=;;E.8;E;DO=17SS:;'X7)\$?E\1 M-)T>=AS3-.CCPI4?P+2]$>9&RPOME!^+I?W?>9&6PS3AT\Q]_0W3]".Z]*]4 M9]_PSU;3DN_*T#BJ:[5.=1Q^/1S^=':NA=/9)+\%O=X$4+XX*&/UB\K5+&-0 M'ON]MKQ--]:#C/59<\7/->X?S(.YA_=)\+?G20A"VE>69>7MY"K.TEASKU@V9^^T+[]U M\5 WOEB$GNN1T!8 H_LT"$.D!)BO M>5G%D_].9_=*^GWD)ZW9/6PCO*_8]OMV?^_!-4Q67$-N8!NVX]F6:;DPW8%K MZ()KAJ]'@6G>QRR0W4P[GZ<0;%.$.B/0C>^5C&]WS'@ (!%%G@M'C'5RTPBC MR-"1@_S <"PP Y1X D=H%)J1[2MQQ(<_3XN+_#K;C2*-#? O&T;NKH ^%W_6 M:W,AI8&!S="P7S>**%-RR95^D5TTY'HS1A998'M^=N<'*CR=)_%*1C0N_>G@P:R5W-"X%$46G;D M4638 2$Z]F%.J$5]F*IP8TY^R4%8OX[S[-[;47;-"R6TAZB)GG9R7MR''C)U M6>_G_=M?*,'V^U*[8!,VX].[6!=^QS<"3.:\>QJ719EZ/?]W;%_R2HMG_$@ MKMZOY6.O-U%>@! NME\7VN+GPD]YIZ4CON4ZNV1#[9S')MHO<5EI9^+;K\=_ MN_=]?19]I_-W/SR\XSH\:E?UT4=_S)(_M&K,N) 5^:Q(^=:907ZC#1A8;,X( M3N3\T6CO'QK@#]>7M-12?@W+$!A4Y5J93N>3*LY8/B\GMUH95VDYNA4U%Q7R M 70Z7N[ X81BO>-^#N\IM#B[7=)&^00:Y_7XEL^4[^@H3[Z)[=NJ^1UMY5[M MTS8=0SY!.P[!0%OH,= M@T:^L/ .,OV(^"YM6OC?H#U0&KY-:9XMMJV4#]\+S:_K&<2@(17H*7>%'=LP MWK_LU,P>^+2839B^YG1JLWE1SCFJ "Z=S4$?#6(N$(9#RSD$O5 Q!7USDTI[ M@VW-C\XTHJ-C*/ADWG4'01T$[16"K#4$4'2\%X/@.\@+6?=/CS2":MIU*;+N9R&WRP$?!/>),(QW83?0QT M7)?L *@#H!<@V_< (-KXZ :9IAY%NA[8R#>Q&7C( !RL>EZOH$C6&/O!F\O1\LU64[8.J MZ07(^FY@,AM? UHT\ @)J>_J)-#-B%"/;UQSJ>T00";4 DR?RG+.B@Z>G@.> M=-8SWB3W@Z=%V7W!DS3KMCGQQAU,ZI%-3'MD9DYR .EP^^C1YSL'=5RL$?J2 M]08%B__HQ2-PA$_BR75\6W((&A??YVFM3Y-<;>0:ZFPG*]AP0]ZAA,B)8F&. M%]E/D/$')#OO<=3&=V1-[WUJ!49HWZ<\F2VG/&':50^PL2_QQ\Z?JI5GHN^"7L]3E^R5A+^-'8CS!UKW9VBEBL/Y[?3N')FT=M MP7FM<[,\FDD(#ELZ "6U^,4GJP1]9DW\"[F7Z#CUN2WH"^V[SH.F#Z)X[#; M13;,E8OL1H9CFKX>>#8)7-V@7L!W]WI\>V]D;N[N7=BS6TP&0JUWN<3?=IMR M_0A&#L_>:?^!CA'69G&A7<63^8L[]N4!0O#D9V/=B^7F^G"]P+1M%$8A-K%E M$EO'R HYRVV,'-O"89/E"X"J\6F__ Y^/NNX^E"NKA79<2V/8M]S4$!=Y :^ M:V+!53VD#FB\3)&78=5]CDS\)N9NQ<8CD0(!NK;\&]D,+$\(__77MT M]% 1(R(%E\;.[[ ,!>NN%Z,:Q M;?ZUWL+Y.<[@Y7EQJ_EY)KC& XM5M;K0>6T#ZG=J[COM.JW&^;QZN?;@)8"# MM?Z"$X=@V GQ+612WPN#0*^MO$WMD.BAB0$?4TEW?#T5UW>9QP@]'NV]#NWO)11TO1,_ HB@(?CX!@+T()X= MV:X0"G#Y[< XB(/?*A$UVGL=&R5LM!M&6X^\*/)-US!!NWWLVH9@8V2&GN]' M!T=[.3=_#+1_OF2-T]CIA:D?>BXX>,7TI".N67L+IQXK+O8=_U31_L>.0$ MH.ZZ(5@=.MQKI_O$\/OS&8!9"/?C5P34PQ>&[*0+<0"![:# _T MH.[B8UNMY$ $![Y#\?OR%AOK9)SMV&;D$!-SURWT"0X%BE.=^D%HH7VC>#MC M.7I# 0WA/C(Z_)8S-3M6W>:LW[Q]S M;/#.7-_R+>0'GH=1)'A+(]MP#?(LN&ULX;8N_.Z.F3)FKA75!OZ96#=M8*"/ MD&];)!#,=!W7=>2*>BC<-CKL<2Z6.<*D>[X1F '!O6%B^;H!C&"R-\[;K_A0N-W&TPZW]RL.=N,C MS,C'R-9]QT8XQ)%C>>*$',^QJ.O;&!W&W\9J]09BA]L/X2UM;%&(#-,.G( O M6X!-#L#3%KREAD6MS3L&]N1OMS"V]K>QAAR1)^F8*6%F\Q@'2R>8!!13X%^ ML6>)@\0]QS7#B 3AX?QM-4\[W-ZS.*R7.[S #\+0)&&$+=LP#>HXM3CX1FCC MP#U,?GO;A-OK_+;2W[8[5=_FK;->EPQ=9)AF%.J^9>D08@=^*/+;3FC3T GU M ^2W6QA;Y[?)*BD46$U/?];>I3+/:5N,BU,78.\>7/3IYV MN+U7<; ;MW59R(XBAQB^9?C$CZ@5U.N2_.-.FSI2,_[T>1)C.V=&UXD2PU0 M]P-NM?YA=!V4>)T$PU% #3OTW#" OVW;HB()YIJ^HYO[_7;S'IRM,R6&N4R5 M=.R4L;/Q75:@D\CS2:A#P&2%D>V:-3L=(_ ](OWZ>C^IDA:N=MB]7WD@ZSQH MZ(-N1[[O&:&GZR;%ED&$/'B>2UWK('M*),L=.MJ]-JFC3MQ6&=!PT\I/M\J MB1R+D@/YW/:V+."USVTK?&[] ;?M_CBZWCCBW[6H8^BN173$%[80IJ;XZAH MW36)8QW YV[C;.USVR9/F3G12+U=[-+)#(SK$1Y4N/M:W M9<%9)[IU%78[G;)+F+O.C5H^M5T:&:#CR#6 IWXH FQ^+CF)R/XWEK1SMLYT MZROL[M@I8:>UUM4 ?*S =ZE!(AP1$X5>P*^Z\/@G&$B/C,.ENENXVF'W?N7! M7G^GX3J6 ;ZV'=K8#S&%OY' ;M\P3!+@ V$WO2L*1@.ZJ2)?8G2Z+N-MX[,- M;$,D'1+'C#"US"!T3+&LY5O@JKGA(;Z=;&%LC=QT =P=,V7,I(T/JG0O\.R M^,3'_,(TI-LB0/:=T/(@#<_H9+>I_F2'+YJ?+*]N^(VG[NH/R4 M#?EE $P;W&J)N(]R&L-$7X]9-5Z<_]^X+#(M-7@]L)B?"WZI71;Y=37F=PK, M^ 62,< K&\$PAEJ:+>Y_0^;R9/4[E[_!4^SH^NI" 7[\E/U>7 6'S+?\7M+Z M/@(RZ!')*S8N):C?9=Q]%[^B@%=_>_QDDZZ\;+8[YOWH,<>\DY:K5+":9.NO M]Y:54*Y=+\28O8CKY+\OANXVUK2QR<"CKAE9.C*HI^,P(*%N\B@KLEP]]*BU ML8$_S"INJA<"\W_,6=O-[Y\NXT;M5BM=V"KI"8PW;HJ>0P&CDU8 M4H&!RW)QA\B\9*(4='EQ(3.4+%-QK\@,.I,/^3R+MB:WO'%^G**X;3D#> 9* MP:[2$NJ!V8RSA%]C&"=)/L_$ 5YEQ8]L+(9E?17S4'6!B?XF7EU@TC2,Q[5J M;2J8:O9<<8GBKUF:Y$.F?3[?FL:51-S7ECZ%[KRJBWABH?:EZ9C,B E%$$T; MYH ,C)C:-#;1P$[PB(G[Q^(7,3S)7.]49>'"<&#EJ-(#Q2@ UD[*^12TZO;; M>RM^;EY6\0F"#HT<(]P4]^9_.29.V/("=#?YUSQ=Z"AH8)"6LWSY$ZAER:KR M$1[C:MQ/P)#33-NEKLJZ[JQ()_6X\3N^K0\]^E7OM"#.8AX'^'DQRXOZ#ODW M'&;^]A=*2#VS@&;B%W[_5A,61HLU?UX4_+JQ,P;5*GYQR.H6^T(\XO!6C>/J M':<]NH.?XR(9UV/5OWVP?%R+ =6(S3C2\Z=Q4V1&X(,750PA#H.GU2T8$'X5 M2EGQX @&+P3HW?+O^71VM]HDC0?I1,0Q[Y:P[:7Y;!R#1=8&\Q)$K"R7E%_2 M$40^2B]J&X M(.Y+?JQA+>:_RWI&U*RLN?TM#'Q"8>46<6$F1;_A[]K':=C6-*N]'LZ0@G./ MWPD&9E\@B,,O.8%I70[OW>*RFVLP^_F4WW<.9KK(I^+M:0;\@S?"%'!13OG[ M@*_ (SX?_'VE>"%8YC?&6R$,XN?@[1ORMMG*LR*-"DR=%C"-5K.Y2O?4@A_> MC--!^NS8"3.NZOI7$(E(B,1Z$)_6(O',';\ L9IG\7R8*P8@Y9Q[+P[N R,5#* MQ%)JG^C6ORX?]$WY(/M1Z2!^X^^#TT&O]>JVIS18L!-4R?D!QG?]GCB#=8.6;*($4_$[='NE-03%$D[[C#=LKC0ZLQ>P!*Q5*G5D29V5ER)'ZAB^]HCLA?]PLAX M(>+W(M3K +Q[JG4'GT^8]C6^9"#:( W<[[]B6A!7//X!5_)-+>]5[>NG&==7 M[9_>V2^++/5L-H&1SBF_R+)_>UGGNDFM(,Y3F2PWQ [))7*CS3W__XE[\ M>A:>?T.TN@=%_MI8\ZF7I$3F:B/JW[$UXIUL+6LXG]QJ23PO1983(OLZ-QV>*N [#@*$%/DR1Z4;[V"&"+V*C1B!^\7].3S3_-.SKZ=G[L6G MTR\O+43N1/RP(OX:Q-J[/?GNLV"/'GR_[(-YA;"\TLZ/M5_FU;]_ ([S3=F/ MX?EW,KP?CI_BDYA7S-#%%SC_+TW$?<-E.ERN'OKCE/$=.:LM;Z>C$922+5M\ MT_["?89G05RQ$^US?*N1.WL8NKS&U<<_+7\,\N'MQS]_Z(^KZ>3C_P)02P,$ M% @ )H:U4-(WR))F'P >2$ !0 !D:')L;V=O9F]R.&MS834P+FIP M9[699U@36[_VAR8*:J2+A:B ;$1@JRB(F&QE*V)$Q (*0E1$FA@1E9ZQ012% M;$5 08F@%$&("!A$2*1+$Y$2J2$@/2$))0PDF3GCUUG)^K0F M,^L_:ZW[_MU7D)_( +#J\$'[@X"LG2YRO+EJBJJJBM6JJ]:L5)MI:KJ*NU5:AJ:6EI:RS$ZJ[4U5ZMK M:FG^OHF< OH;1:5E2DK+-%>HKM#\?V[(%T!M*7!4;E9!;A,@KR:GH":'5 -8 M )!3DOM7 _[=Y.31.2Y17KI,116]H'@5("^GH""OJ/![UNAH)#H.**HIJ6_< MMF^)AM-YY4V!FMMO/TY;JK^_H$+K>*O08,>%:W>6J6CKK-9=8[C9Z _C+18[ M=UE:[;:V_?O 0;M#]H=/G#SE['+ZC*OG1:]+WCZ^?D'7;]P,#@D-NWLO*IIR M_T',D_BG"8E)SYXGI[]^DY&9E?TVYT-A4?%'1LFGTLJJZIK:NJ_U#3_:VCLZ MV3^[NKF#0[^&1T;'QB=$TS.S<^)Y:&'Q=UUR@(+<_VK_95UJ:%WRBHH*BLJ_ MZY*3#_Y]@9JBTL9M2]3W.2F?#]38M/WV4LW]C],**I;I[S@NU+IPK55%V\"" M:RCZ7=J_*OOO%7;G_ZNR_UW8_ZFK&UBN((5>=.J5 M#^;MJ,I1FFTR(*LOO1":":9O,%T\R=PHNA3+)>P(?C?QT?5 -@(DLMG&*N3+ M_K5SF!X\-]W]Q%E=V[G]PJ-XJJL^^MZ""D?G/[;"(*8K M29QQ*KX!>FF6N6?I#53YJ2[-YE]5!/5U M7B_=&6[J1>F6UFBF!S8%89=CPM-0="GH= MDEZ]<'5BU^#!>W/13M-?:4)M1;)6[Q5Z\^BRMI1[I=CT$\EOE:SFL ZID67AC.&V_@T/JTJ/!-^TCFQ//6N]DL+:#K+/D&? ,2W^N6LY4 O(I=P, M><;KC,/T>LPB0 +VJO2==V# 'NI9RA4GDRK/IEDOB7Y*V'0A;\ M'2PRYQ^X89C\#3R*+Z$)CC+(DHN)G206T"AXUZCJK5+"](V^ M8Q'CZ74(H/<^_!!GN@9\9DUXZX?SE M7'F31>0;5K);9*WFV)"(*0L-MT* +1P![I30DK?L#2%4FR["5[M2JU=X"DH) M.S(^@H(\/I2\2*KL7_%=JI&10:',AN]=\VU;3?D+XS4(,%3\^:Q.K4 /K"R$ M' >IZG3UG^/3-L2Y]M@"=)!G\C751.W1V]5'79B-:6.UL>O6[SZJQ@ANEZ;) MWD:@.T=U[=#HHYW7GQ)(ZP4_^>^W2;)9-]%-N9Y^'0'N^$ Z$L_!F^6#GP81 MP*[U';-E^7-460I!L;'1*''M\XM)\T_ =_$"]@1#JC'YY6XEMI ?G6;@X3YZ MWXQX+%[6\@D+6]UA_?W-+Y)@V8Q AW5^ E1ZQX)_:$'<4/IG=PT8GH[60E[J4SF0-9-+4TR1X MBHV"K_GSH!'0W\-.5JT;IX\ KTVX[AJV3)%S<=;X&O=W;-?8V;>D )(.YW$W MZ_37L^->]>TSH/[T973V^> =P( 4.E;U@-R/ *1G]QB_PTS2ZM[KH M.2R*5D6$&N0?(*1PJ10;8[D9@X*/\J'@Z)N\F4.+>H@$NQCCAZTUJ>L[Z_9UX5M J!/B8GM@_O8S5T;B.-O?M MEJG3 4W@/_L!B]9J7.BN8XI%)_%^%#BL;B$F^9;*'^FW5+;8+'B:^6&+]R' MWG0$8!7)^<5X:0*+6^C=KQ @M17D=*?>0L_A,;D#VU])3F)GNLTEDK^TL[/3 MDG?;U6]>3/SW;9:9O:;(+A9DM;?]>P!(C-FBN_F078M!H,Q'WF_+'Y?BG*;M MF1FOY&/0BU\]E%W,QF7>,DK/D>5@%O@Z,MEK_C&PQ8G1/L-8@Y0) M5^"/]+0G%Z/(H8J@X+MB^RD\WPV_(*7 ,!WJ2 8B-9W^6NX9]X)=CR]F\+/\ MA<\SA5GW#*(1H%;QPD@0A7)TW1PL9?%<["67R#^(PM<1JNNCJ4;24\G?0]ZU M2"5&>[+PCMQY>L/S3)I3::*]8?+$1&A$W1/'EWW=S"K]>F8QW$'DCGVFK7TY MBG5! *\TT5QD7&,E#B,"ZP0/P'/%R0%!U:Y/4[V:A]L_2XM@XXND*5/R6[@% M7TB*9GES5D;2CCXB3L;7P;3<9AU!/L8]5U:- .>GJ5O@T2BNGV0ZH!;7KA+4G/)5<^"]R]JB)EF$^880;<^SD8(J>)!2 M[C2[VWP-U'8:2AARL"5V_)) UL_)*+[OL"<1S6J"O$4M3SDB4/2 M0T2>60T[Q*O=H!0XF0%.7<]KZ2*)-_T@K[(/&"1J%;ER'N$[_V:%]5?!GQ3F M:;+21?K/P''WYQ^#UORSF*DQT%78TO A] 2ML\"U)1R3D1X#S?#NL-;C!S*Q MNL5837(K(VQ)0HZ';09TI7O/DKA.E]@C/)MZ^SHPQ8O,"&'5:#-7"O,+Z9SZ MX2[?CR<\CH _8U77P*$VI,%&EEY(HYMH29JDI\]C,;R>Q7D\?TSY!UB(X5D. MLKHI%9;P%FI-H(]UA$[+)9I?U&AHG].9EV22>/*'U $!% LA!M<=1VA1"9ET M[#0[ ;L/)?H;@?-@-'-!%@_K(D!EFHQFH\/]M$FMO^YBDLX+!&BL9I4ES?F) MUP#2/X4D_GE1FSA0Y-Y)#1QT/]WK^R$R=<96I"?)GJ<+R3,CCI 2.0^N9Q6) M$R3'0N0=+O6S)>:N[Y-XW8F)1Q%@$Y'K=66B*H-,1("*0Q&V;Z!X<;[(2$Q, M,._:5%Q8^@3'\HW%D>!-S/NH9N,@LM1>I%.]WN*Y0]Z3=;*%I(A8!(C(C0%D M6]-C6CIV^N]5=BAMWZF:G;>?5 MHNX>F7+T/=5PQTP3M.<"4?R,/:2=,4B]3V,H\Y=O_)#H4[S>E6C6_#NKUDQX/5K"?Y^Y+60N6)2) .+SX"M-,PT"%SD(P=E9F*]D_ MT_1CIT$)NLL18+IFWF5V9X:?TT2W>VJ:7'-YN[TU6-JP&K2&PYCFKJZ^+&V; M\Z2LOBHPRRZW+S)QL--]W 7Q+_A)RN74:5>Z"GG\%J$DR<3]YE6_/!D/$, M!F;*#26$5YA+*,TK#-*@+4DUQC9:0KVJJL2@U?0( ODQ/LFL3F*#+P.E8".] M'OSH7^@[XQ%)=Y)H7GM#"AQA-O/G3R# .GHN @QD$S7PW%VRUQ0*?WCF OQ3UB -@0Z(L&<@C"CX;]'>K)?^V6,,SK@S M @0U.7ZV<8"G77[2A*?,'SDS=Q5"YU^/S1-]?UQ!GVRO@&X6A^D*-%DL/)6; M<>'='7A)&)SGJPV4RQ-R/Q4)&(;#OSR"J+,A8 AG48DL9(_82=776J^2@>P#GJO=-@5K0MLE:SI^K)XKW]^3]\84 ;9JL9B< M&CZ1MCA:A0 ZD LW.+KL1K:'>_=8_\9/R6V.,6=H3='5_:8 5&R-"]PJD6XFJ_02+#T9= M-ZPBNH(1@&SY>U47[8F/.$)"RVJPM8KEPD=J48X5]JO*DN^7GY4]"B9^L#,H$//?N7\ M=,K\56\8N#M#KW4PLF>RB_T=\(2B9 1P^IS4&-W?:2I B>Q#+O&"#UBDP[_+ M+==Q_&$APU0[ET9&Y;CUN-5P\26/,SM0%M.4DRPC1A$_TFI5Z0^(14FQ-_:8 M[B?R)@DTWF?\9I?8Y<6GC/&".LED(WWY M&[6ZS\.2YO41#]/&+>$_12MI&2B!9_A9OVQPRY)9)-OU_(7-1P A@4-AZ.G( M:%ZB]0O)A!9-XMX&77"T']]7@P#%)KRP$?*ZD%ULKN"V#9Z;@H?$/[:>_T"% MNUZYCF?+E\W8^2^/;]P09['0US+OOP"CWGA-,IA42UT=DFJZWR>@V/1PJ*EG M#(HCQW];[#"YEMS+00^F,[F);-$^E-+ 9'Z$&PN'WA7" @389TZDX/2$XHS! MO&MM=JVS"\4.KE-$,]4]IQEE5+@A#XA\*>3 RPI%CH-VMV8Q&G5# 98$JO,' M0E%A:>+HM]B+"TDW._(I\'I;$1&.,4,3*WB%!26_S2)_QW],3?$-\"9Q]WJ8 M^'@>&J3":G\OJ(6@='%CG%7(JA%TM]6!NF4[7T-M1]HMP&5EF>Y'IR:KZOU2 MCV^6,4E)'=3ZO[ GR?4L>3/0FWI7C--J-Q_LV$DM:@X.#=7F/SDT%>K>*^MU M*4:#6F@=7UFDA[_'6A)Q?K#VLGVF;Z']4@3(;-J%OE*J&O%NMP,G!K7!73N(R&4INC6P?-ET)CMH]3I9*@;^ M635-_R:X!5LR(2\1X8 HFL:E0X?-KI_!?4\$<EZ) M_MQ;M,Q-=BA<[4!Y:)3[K&4U=]E^X-1P"\1FA;&2A50A?"^7ZII MVZ]XCP_,>,>2DK8+/9J2XY9G=J&ZNFE? C_&I)>Y+$)56/<%3^GT4!?V?2A^ MNK6-$!02W!RTPS,B/[SP'/GD,>5A!.!'B>3!^]@B?$Q6:$1CP*Y1B5DW?FHK MWARFC#CC>75<"5$3_NZAU$;?I-Y3_]: NHY6-PS/(,#%3+@M%?-9:%G'6G/: MPW8XM/3I_'O6//>YM(8D)7\B4<@6-&Y+7!%&TY5J';E9O*=01SK;C0#;7?BK MLB(4S]LN6$BH-:.6LK06MX5B24MOV?'M4_FD+SBK5J9!"-%1I'WW)J/;:W;_ MH5_8156PR-KED"M+YT4H=FM+UV![PO<)US]>7?(HR*E #V)85&^ZB;]5:BBM M52MX&[V*M38D'UP3PG)C3]4M'LR(W#F$^HI='S&'PS"BXKD*LA=EML.-PQY^ M/18ECC(T>9Y!;27151I';RUQC4H[L6IQC!Q>/2>POJ[CX-A*A#83;WVC#; T MH=(0RLNW'GF/U+WA,_NWUK-]B7^6K3 M#!TUZ/Q LYOPSK%4E$KN1/R<=,T2CZ(Y1'<"MNBXJ/ M=O-U*BS9\T8:X]*& M4X+"2B<.N)HU[C_V&EU]4R)A5W0+M R]%VMHSGA[(#DD5@U=O^AP7[X".GS)8XX=SYHD/,%"TBOQE78 MD+ACQ5Q/%J__\H^LI,\",->+;I0$+_LLP:,)??O)5I"]UWD,Y!\&JCZCK^Q- MA$H1IQZ4?^=6ITZ7)8;R8]I,>M0V5O M$SCWS7#!1=0^+4O:HC(9FJ9&_9\#)_+1K"" Y7JZ*WN,#I])1OG?9K",E M;'U> R9QD' @V5$R/H^2]1U(6;)>ZB![79R='S [V6RY/]5Q^VBU:_71?UYR M0N.#FW>P>?0*TMU%G2\TBC7QGLT>-6UG3W,+&CG43= \_Q+HS6C;FY8V.(* MF$RS8!4'B1=8>2K;76HL]((M_,]$E%^#.XG08@(XW.2B]L7@WU[=@8C&R M)J$B_FNJ9:STK>Y:_^57&ST #KJZMZY1^T/4-1 @4)4&[_X+FTHL\.;I&_&- M,R;(^J+ULJDH[FFPE9=O*A_*#L;6,4"A::03 JR,@FX@@"T]!C^-UP 2\ >1X&,6JLVR2F,[+P/=OJ45K?.R+H>7\+FUGOT MB-:*]T,$47A-?$A\#5/SX:G.K#BK_H&^(_?>1?RQH.N?!A&$RE]H\N<[-J+X M+HO5SMA"",)V9_ZS)[N2UK_CF/(;9WR,S3YO+G'E1&F?-/548@K)L+<%KO8M MZ:PY%])6L>A8C57Q(Z]CFY+9;_R.I82G@-OBPRQ/]99]5YX9&C)?-4'4PAGX ME5:GWNC,I?N1 E&%9>R0-NV4&5]*6(P#7&6[R6-$VM4EM0J>S[F09JB;Q4@187-*P MJ)+;W5/CO?R8+39IG6^!1JO+;><_%)I '_.X9&4>7]B) #5ATD]J\,2/9HS M;&KMU-^I(RR,U&V0J@NW8W6;^?5)IT4N]TG'^[M_X!>\/\M.$F35KK(RJ%AB M)=T+#85FM0S%JDJ">6JE;@:,H$V;!>73KW,Z@ZN(73NX^ J6!F859%?YY[CK M]P<#A!9KWY=J3"%Q6_(MG)MP7JJ.K<3^# OME/KFKW#AC8M;WB]LPEIB=_75 MS_NWX'T%T.:6>[!*A)I(.=8"K^&?G)GV9D%=-7QF97/L]H.<&RZ2N<6$LX*X M,LQKZ2%A?A:WF=S"[]Z5H<8H97?!1$'J*+XDHT@VL(FR5[#("Y!1W M\E%X+FD99L!6JZHU)$5R MIF34@"H\R(:1U"JRBG!%&:N,61+I,847Z\MZ06BF?L%EK#A$4"WHPG.]:TD: M8.4^-,&N,"O(";4'D@EO7R_HI/-=-.46,E"=^02A0KV,P5\K8]EX>*'N<_$S M=J[;\3^Q4XPKZ^&:\V0#F-O&;^L&J)BZM!6'7O3T;PXK)[^5GI8EPKK2JVS3G=0U4,"-OOT_.#QAO6E[*\]!PIRPGL\EHMSF MC:'@Y?.+UU(50ZZL7Q-YV")NXD"R_?(85K"@\)CR6Z<#:$%):(@)A5YL;K?1 M&5#U#;FS>^?#GPC0+^O%2HXSB;('Y*TA1@.DVI RWR&0KQO V^H=U[!G[JH+-5(Q$)/V! +]USAKG^U."O;N;88_E%._P,M:T<#A MZ"@;LUZ;!#N>_&B4@+#N+>,G0@%BW4@?:Y[N&/G+%5) M=85S)=?,-#^MW2RX;M.+7/#=*\PKG_088*%-G"=+V(KW<5AITF/LV6;CYJE+ MV%._Y+C7Y+ ]G_@,5&/J0+E<7+%9TF"SMN#@)W@9"C=.@0AP=EA")Y8XQ#]: M1]9*R/=90XS9ZO6^8[;'X7CE/DEC^$_GDR1(5=YD?'O3-',)[ALA6;EI)-1T MW<7R-\2M")#74D>[@RT"'Y'E)WZ<]=$AWWRYK;GV\;7@'D<$J,9+?(G7(ZS0 M-Q4KM1'9'*L;]#&38K/!1L==^*(>LKH1B@QQ[%-#F)\Z7.6'!J'G6O.+EKF] M_7$EQA@!;EEYR4P:Y\PA0TZTGB.4!/6X%!.G>MT.X!% PR-?7RM^Q#RU]&K2 M=>KV:)V=C>7=IH=QEQ+N(, 7:@9./P3[A:7VCA]0YNV?Y9?8>6U! MF-';XX2=&A6X*.DE2:REEN/*MZ[7@^-971XDMNGI;@Q/3GB7\-QCYDA[,1L[ MJ]YNH#^]OW@R51TR&< #FFCL M(U^>(:1F6&7-?V!$,PU\K-NO5G!C39Q8A77UIIDOA#T@Y]IEUZDA_.>U2=Z2 MG9O$Z24&4V&!]ALK$Y\DOGKU?_T[_3_9%9"N_P!02P,$% @ )H:U4&4Y M"?OE,0 G^H! !H !E>"TY.3%U;F%U9&ET961PU]ZU/; M2-;WYV?_BGZ8S#ZDRCB^ #8AFRH&2(;="62 J:W]]%9+:MN:R))'+>%X__KW MG-,MJ27+8&P3?-%6;0;;4E]_YW[Z](?_O;@YO__/UTLVB(8>^_K'+[]=G;.] M@W?O_MT^?_?NXOZ"_7K_Y3=V6&\TV7W(?>E&;N!S[]V[R^L]MC>(HM'[=^_& MXW%]W*X'8?_=_>T[;.KPG1<$4M2=R-G[^+"C\B-FAX)%P6"Q=O\_^[0CYC379P4'ZY'DPFH1N?Q"Q5J/58/\.PF_N M T^>B-S($Q\OOP]' MKC=Y?^\.A6378LQN@R'W3^DWZ?Y7O&\V1M$ICA[>_/B!,Y\/X5W9X,U.MWG8 M;5IV^]#J\I->IV4?'I\TVD>BUVWT]CY^>,?A__16\D_2L^?ZXF @<"[OFZW& MSZ>1^!X=<,_M^^]IAM/]?\!ORD;N^@,1NE-OT,>QZL(*/ >:T&O#3D[JS0_O M\(%D?,8HK=#X.,]X;=@[$;[(@/^X/OOCXNK^\H)]O;UAGVYNOYRQ3U?79]?G M5V>_L:MK^N;^ZN8Z/YO7'_C%V?79KY>W[/SF]NO-+0V1G5U?L,^7[)>KFZ^_ MGL&XUVW,98M]?G-]<7E]!]^=WWSYY>H:_LC6_^[^[/[RR^7U/;OYQ"[/;J^O MKC_?S3^K$7<<(/2#*!C!%Z/OYC0]T7L9$KBXO#N_O?I*&P*COK\]N[X[.W\> MA*8&OO1 ]S[>^'__J7G<./W"0WN@_FPW:\3G:FP4AS+FT&(4L&@@F/@K=J,) MX[[#N)0BP@?L 9>"\7XH!#+3&G.(EW+)@A[[)*PPYN&$M8ZPS>:)?I?)V)+0 M&KS@07OPHH/OP&^AD)'1 V+)2-B^SB*O__4;;4:IU^3OL^2ONF'YNG;&K/4 M("T1C87PV07W.\03."UOG-BRD$F4X2?SJ%S<8#7@XY,Q" M,22D3'[YS>T)=F>[PK=!4)B_ E%G?68ME$]ENH-T5M$@#.+^H&QHM@@C[OIJ MNR7-GYZ2,AZ.B@]Y+K=<#]X5LH;[-Q:>A_^=,66-)J,!1(7KN#R$%M0$:ZP' MT^#,YG*0H6T$RR[P 3X:A<%W=PB( 1R]:37J'09#\*"7&K;V)VP1@C>=AO-G M+"/$"HZP=#*%)AOUPZ1%_'4D0 4)4+LG M@UXTYJ& ,7'@%/$(""*B 0+E":0VH&!7VL&#""X)+.'8C!;GI M):FI[S5=<4\&C,0/D(_KPW9R%J6Z(),B?'"1-%(>I)J>2:>(J P00]=W8;V M*3P(FEHP$HI%P+M)VPHL'%<&FK)BZCCK#QI*&K2#V(\(O_!?%UJ(@7^E3<(@ M<>EQ\#T1XGPT9]5CJR?"X-E\_.\_M5NGKRM*[HT]Z[D^!WZE""Q'ETK&%$B9 M-BQ'>>]7N1(1XA^VR//TO/^QU]BCSW+$[>2S[J1\:69HZVQZW2+08R,G:6WL M.M'@_6$7VD'%/'+P1_W'.WHT]SA0'=&,5D=@#'N/;V2A_V3PJ,>\;QVJ7A=8 M0F!)QX5%U&.?/=+3YPUUD8&]:=<;>2 !P_%1$4$^)1S)>F$P)- IS:&IU8X8 M%(QP#&U&H Z,8LL#?A#T@ 9AL8AKN2#= +Q#H.N[*+"_$<%_@7]X%(#^(W0\L[@G*%Z.U!=+-1[YH:1CF:78F* MN%)Z1!P&!X[P Q!=2E4&J/Y1OZLS)_ \'N9^\P+<>!$.081;)*FP.2E $#ML MP+T>MH@D1&L1?AV0 MU@[_SS-4,,:'(K1=4/!''%1S \,K5<"G0?BZ;JF]CV=H,R+K5Z83&!^!A68+ MT:2V8& 98T]I/:21/X#]1383+K/M!>0DUR8\63+PI;;XZ,9CJN"A2F:9:4F7[VB=[#F4:\!'AQ\I%D#,:E$KXIMEI MJ+^&IJ8(#:*< SOTQF=G8'=XK-U(/%WFV/.^&LD]D4QWR/\,0NVS@,]DOI@# MG]]7H4?:;1TQ/4C"Z1C^ANG90=^'78.V^K1:?C:2O #_*^9AI*Q^G(=V(:C% M=L$X%[-&ZK@.\X,(^AJAW8]6/2,K6/1!,Y8#MZ>M:*XFS00HR_"V'HI>JO^3 M.=,6!J3L/J0L:#;VM,N(IH7=6>AF0(^# XT) MXCP(BZ$B.^%+^ X 9L%(D(W"@I,' =4Z'OHD1EW)+([/Z<4> )$ [-"3@MZ< MP'.5BS5;Z[0=(HG$YYCXMW+OZYYGO6OZ$9F&AAH)XCI\$ =!'.'PT/O40^CU M79+H&A_:G5'P]B4NJV@:G E'R,-SGTN"1BQQ';@5/(BWZ7STV*'3PB/:2T/# M FKS)OA,WL,G:TA>'GSA]F!%,N :GD'0E*4=NA9YF_1T; 5X;!!PC#Q*3729 MC=;4NBQ6LEV"17-[,UQJ):LWX+"QMAV3*0M/_)/[Y*O7-C,,[\P84J[_##ZC M0+ J^]V(GVX&B1IDC!(M[9!O)@1!1 M[E44,K\K'NE-V"VQ'ISJ)Y@2:S8.?D\%6\))521"BP<==>BYGG R?^6=@#53 MKE]SP]1<^8<>JT=UF<06PJ*=Y A:3@67 MT2YNA[;,]:E'[:8%80LX1(7 ]R8K(BO$J0MD17@ :K<$J4Y*-4B(KCCD%)^) M](.?# F)%#>#/%-"5'&O:5IP/P<8H(/HFP.AMR %>_%Q+++ M)X:_IRPATR\?F:^%<;E,T]*B#NDY&95P5,@ \9LIF$LM@1,(M0@$F)#$%32C MHD3(&]4<2[@;3%!/%R!KK$&&7M4[.?%7:LF^MLFP-.X,@C8U&X."&7_@KD?V M.5<;$8&)3>$VD\QTV#F1Y,I,*((6#'+>5X.PA.<*#.H0;+D$5@%=U-1[F@,I MYQILFZT&_: 4 !!.-D6F(Q7NH;$EH9II,%.+V V%Q+@';^K(FNI1R5[]C/@^ M@L854QGP!\562 5&;"5C28/6NRTHT(X$$(QXF.9G%;6%H8@&@4,6EDW1-XI( MHK!.8!?I_"XS%!W"RH*" V^$.&MO4IM3US9Q"P:>8F1*>U1[VD=V.K7LA?RF M'YYWL_>Q-/-J$&8NK[XXL&"EOAV0!OV>>V,^D7MZN,].U'H)..6-C(QL%1?V M)4; UHR""#4;K9$B;7K#AL]WVO( $E+*+ )^>B_YVD-?* M,L(0M4Z8L+6FBRS 3!H@1B:>,<:<3>B&QC!['#X^<"^F9@VIA++5R+?@N0E? M","TJZ+>:C[$5,E4!UT'A!WB7(\_!1CAZ%/$HR$+>V+5A2041TIR,@.@3 M7\YTH]8DI?,R>C* M60D)-QB'D;02B@=7YG:>JXT Q4C.H;&G)NO0FLVZ]>3(.NHCFCS4&:>AQ0G MF?C(Y0FI-T@X0WMR;@&>TPVUSEA3"2&. "SIR 6IZ%4@6=TOY2)&0>?MIYF8!0]!-12^H9-YZ =Y4M"US>3&Z: MMN;2< $*"'HM)Z-+=./I[,M]O6D1P$L>>HJ I/=,D_8S]3 M)M]7B7"]Z'UCP1CXOOMV_>+?18]'@I\G8T.U6;$,G>JF_29IPQ@ M>4[0NL&\_K3Y\]39A\_<9IZQF\P[:#+(XNC/?#^&9J9=\_]*E6W*'5%^V MA MBZ$%:D=;.T9/697WL6+(;P+F,ZZ90WW&.#<&_TM'IRAWJB*"51/!.E)!\9!/ MCOUSQ4@?C_!S;VH%ZZT\G6OGR&TMYW>P= MMTZLH^;)]#GB-3VLN\5G7I<\Z?ICYK+_1ITL [Y$CH,DHPT$KOANBU&$?E_U M,_JZ8F!$;U]U#C,H>R$WTLPQ&0U.R21ZWT5=17TV>_31!/3R?6HY]BPI_IC0 M+HQVR,.^ZZOA\3@*DB^H((#Z1DGQ9@-6PPI"1X0'-IXU&$GQ/OECRKF6J0+P M"(S0_\=>\WAOMNA7?;0[/QN*0OZWYB,_/?;;[)]:/[*S!7]:[+7N2W;VM.)F M!5$4# NYZ !C$]?F9_5\[BL%OY;"OD%.LYVXW>>R@ZYV!6$R;KF^ET'W:._Q MJ6JZT!-ICKXS,DS83PWZWT)+,7/B4VQGH:F7,/-/6B_\#^J%E^5ZX2P];;< MT7X%/#QC)5X,(4G<]OF>UQD-?I#QZ!&[ZA%+ZF@4@?K!09N )CX^QV![033B MR7D\#/]^X#H@X5>AKFP0'G4OI+9,=?'CP:HB8^L"5;6/^U8%V/4![(_'Y-

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ilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 16 95 1 false 15 0 false 0 false false R1.htm 0001000 - Document - Cover Page Document Sheet http://www.danaher.com/role/CoverPageDocument Cover Page Document Cover 1 false false All Reports Book All Reports dhr-2020biopharma8xka.htm dhr-20200331.xsd dhr-20200331_cal.xml dhr-20200331_def.xml dhr-20200331_lab.xml dhr-20200331_pre.xml ex-991unauditedproform.htm dhrlogofor8ksa50.jpg http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true